In Vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel

Mitochondrion

Volumn 13, Issue 5, 2013, Pages 464-472

  Solomon, Melani A ^a   Shah, Anee A ^a   D'Souza, Gerard G M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Liposomes; Mitochondria; Spheroids; Stearyl triphenyl phosphonium; Sub cellular delivery

Indexed keywords

CASPASE; CHOLESTEROL; DNA; LIPOSOME; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHINE DERIVATIVE; STEARYLTRIPHENYLPHOSPHONIUM; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OVARY CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

LIPOSOMES; MITOCHONDRIA; SPHEROIDS; STEARYL TRIPHENYL PHOSPHONIUM; SUB-CELLULAR DELIVERY;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PACLITAXEL;

EID: 84882824819     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2012.10.013     Document Type: Article

References (44)

1. Andre N., Braguer D., Brasseur G., Goncalves A., Lemesle-Meunier D., Guise S., Jordan M.A., Briand C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res. 2000, 60:5349-5353.
2. Ballatore C., Hyde E., Deiches R.F., Lee V.M., Trojanowski J.Q., Huryn D., Smith A.B. Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. Bioorg. Med. Chem. Lett. 2007, 17:3642-3646.
3. Bergsbaken T., Fink S.L., Cookson B.T. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 2009, 7:99-109.
4. Boddapati S.V., Tongcharoensirikul P., Hanson R.N., D'souza G.G., Torchilin V.P., Weissig V. Mitochondriotropic liposomes. J. Liposome Res. 2005, 15:49-58.
5. Boddapati S.V., D'souza G.G., Erdogan S., Torchilin V.P., Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 2008, 8:2559-2563.
6. Cabral F., Abraham I., Gottesman M.M. Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:4388-4391.
7. Cabral F.R., Brady R.C., Schibler M.J. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann. N. Y. Acad. Sci. 1986, 466:745-756.
8. Chipuk J.E., Green D.R. Do inducers of apoptosis trigger caspase-independent cell death?. Nat. Rev. Mol. Cell Biol. 2005, 6:268-275.
9. Cummings B.S., Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302:8-17.
10. Devalapally H., Duan Z., Seiden M.V., Amiji M.M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 2008, 14:3193-3203.
11. D'souza G.G., Cheng S.M., Boddapati S.V., Horobin R.W., Weissig V. Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel. J. Drug Target 2008, 16:578-585.
12. Gillet J.P., Gottesman M.M. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol. 2010, 596:47-76.
13. Haji-Karim M., Carlsson J. Proliferation and viability in cellular spheroids of human origin. Cancer Res. 1978, 38:1457-1464.
14. Jain S., Abraham I., Carvalho P., Kuang Y.H., Shaala L.A., Youssef D.T., Avery M.A., Chen Z.S., El Sayed K.A. Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling. J. Nat. Prod. 2009, 72:1291-1298.
15. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:9552-9556.
16. Kobayashi H., Man S., Graham C.H., Kapitain S.J., Teicher B.A., Kerbel R.S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3294-3298.
17. Kroemer G. Mitochondria in cancer. Oncogene 2006, 25:4630-4632.
18. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G., Nomenclature Committee on Cell, D Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
19. Kuang Y.H., Shen T., Chen X., Sodani K., Hopper-Borge E., Tiwari A.K., Lee J.W., Fu L.W., Chen Z.S. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 2010, 79:154-161.
20. Kunz-Schughart L.A. Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol. Int. 1999, 23:157-161.
21. Lang S.H., Sharrard R.M., Stark M., Villette J.M., Maitland N.J. Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. Br. J. Cancer 2001, 85:590-599.
22. Lee E., Enomoto R., Koshiba C., Hirano H. Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. Ann. N. Y. Acad. Sci. 2009, 1171:132-136.
23. Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 2002, 5:349-355.
24. Liu C., Zhao G., Liu J., Ma N., Chivukula P., Perelman L., Okada K., Chen Z., Gough D., Yu L. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 2009, 140:277-283.
25. Mimeault M., Hauke R., Batra S.K. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther. 2008, 83:673-691.
26. Minotti A.M., Barlow S.B., Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J. Biol. Chem. 1991, 266:3987-3994.
27. Modica-Napolitano J.S., Singh K.K. Mitochondria as targets for detection and treatment of cancer. Expert Rev. Mol. Med. 2002, 4:1-19.
28. Nicoletti M.I., Valoti G., Giannakakou P., Zhan Z., Kim J.H., Lucchini V., Landoni F., Mayo J.G., Giavazzi R., Fojo T. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin. Cancer Res. 2001, 7:2912-2922.
29. Ohta S., Nishio K., Kubota N., Ohmori T., Funayama Y., Ohira T., Nakajima H., Adachi M., Saijo N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res. 1994, 85:290-297.
30. Olive P.L., Durand R.E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 1994, 13:121-138.
31. Pantazis P., Kozielski A.J., Mendoza J.T., Early J.A., Hinz H.R., Giovanella B.C. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int. J. Cancer 1993, 53:863-871.
32. Patel N.R., Hatziantoniou S., Georgopoulos A., Demetzos C., Torchilin V.P., Weissig V., D'souza G.G. Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J. Liposome Res. 2010, 20:244-249.
33. Peng S.X., Ritchie D.M., Cousineau M., Danser E., Dewire R., Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J. Pharm. Sci. 2006, 95:1984-1993.
34. Rao S., Krauss N.E., Heerding J.M., Swindell C.S., Ringel I., Orr G.A., Horwitz S.B. 3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J. Biol. Chem. 1994, 269:3132-3134.
35. Rao S., Orr G.A., Chaudhary A.G., Kingston D.G., Horwitz S.B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J. Biol. Chem. 1995, 270:20235-20238.
36. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
37. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 1997, 71:103-107.
38. Sun Y., Zhang T., Gao P., Meng B., Gao Y., Wang X., Zhang J., Wang H., Wu X., Zheng W., Zhou G. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. Breast Cancer Res. Treat. 2010, 121:591-599.
39. Sutherland R.M., Durand R.E. Growth and cellular characteristics of multicell spheroids. Recent Results Cancer Res. 1984, 95:24-49.
40. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
41. Tabuchi Y., Matsuoka J., Gunduz M., Imada T., Ono R., Ito M., Motoki T., Yamatsuji T., Shirakawa Y., Takaoka M., Haisa M., Tanaka N., Kurebayashi J., Jordan V.C., Naomoto Y. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int. J. Oncol. 2009, 34:313-319.
42. Tiwari A.K., Sodani K., Wang S.R., Kuang Y.H., Ashby C.R., Chen X., Chen Z.S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 2009, 78:153-161.
43. Van Vlerken L.E., Duan Z., Seiden M.V., Amiji M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007, 67:4843-4850.
44. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3:1-19.